Ovid Therapeutics Inc. [NASDAQ: OVID] closed the trading session at $7.37 on 06/18/20. The day’s price range saw the stock hit a low of $5.7201, while the highest price level was $7.80. The stocks have a year to date performance of 77.59 percent and weekly performance of 52.59 percent. The stock has been moved at 65.62 percent over the last six months. The stock has performed 65.99 percent around the most recent 30 days and changed 241.20 percent over the most recent 3-months.
If compared to the average trading volume of 838.50K shares, OVID reached to a volume of 12757808 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ovid Therapeutics Inc. [OVID]:
RBC Capital Mkts have made an estimate for Ovid Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 04, 2019. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on April 20, 2018, representing the official price target for Ovid Therapeutics Inc. stock.
The Average True Range (ATR) for Ovid Therapeutics Inc. is set at 0.66 The Price to Book ratio for the last quarter was 7.84, with the Price to Cash per share for the same quarter was set at 1.16.
OVID stock trade performance evaluation
Ovid Therapeutics Inc. [OVID] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 52.59. With this latest performance, OVID shares gained by 65.99% in over the last four-week period, additionally plugging by 65.62% over the last 6 months – not to mention a rise of 314.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OVID stock in for the last two-week period is set at 72.60, with the RSI for the last a single of trading hit 76.25, and the three-weeks RSI is set at 69.94 for Ovid Therapeutics Inc. [OVID]. The present Moving Average for the last 50 days of trading for this stock 4.41, while it was recorded at 5.84 for the last single week of trading, and 3.47 for the last 200 days.
Ovid Therapeutics Inc. [OVID]: An insightful look at the core fundamentals
Return on Total Capital for OVID is now -112.86, given the latest momentum, and Return on Invested Capital for the company is -111.11. Return on Equity for this stock declined to -111.11, with Return on Assets sitting at -94.11.
Reflecting on the efficiency of the workforce at the company, Ovid Therapeutics Inc. [OVID] managed to generate an average of -$1,024,767 per employee.Ovid Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.10.
Earnings per share (EPS) analysis for Ovid Therapeutics Inc. [OVID] stock
With the latest financial reports released by the company, Ovid Therapeutics Inc. posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OVID.
Ovid Therapeutics Inc. [OVID]: Insider Ownership positions
There are presently around $91 million, or 29.20% of OVID stock, in the hands of institutional investors. The top three institutional holders of OVID stocks are: CONSONANCE CAPITAL MANAGEMENT LP with ownership of 2,580,878, which is approximately -10.662% of the company’s market cap and around 41.03% of the total institutional ownership; FMR LLC, holding 2,084,900 shares of the stock with an approximate value of $11.32 million in OVID stocks shares; and VANGUARD GROUP INC, currently with $9.22 million in OVID stock with ownership of nearly 14.138% of the company’s market capitalization.
Positions in Ovid Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 28 institutional holders increased their position in Ovid Therapeutics Inc. [NASDAQ:OVID] by around 2,145,273 shares. Additionally, 36 investors decreased positions by around 4,111,752 shares, while 10 investors held positions by with 10,592,310 shares. The mentioned changes placed institutional holdings at 16,849,335 shares, according to the latest SEC report filing. OVID stock had 11 new institutional investments in for a total of 549,235 shares, while 15 institutional investors sold positions of 1,372,664 shares during the same period.